Esperion Stock Gains On Strong Phase II Data


Shares of Esperion Therapeutics Inc. climbed more than 19 percent after the company announced its Phase II combination cholesterol treatment showed tremendous success in lowering low density lipoprotein cholesterol levels in patients.
Source link